CARDIAC and renal events are significantly less frequent during
angioplasty procedures using isosmolar contrast medium (IOCM) agent
VisipaqueTM (iodixanol) compared with procedures using low-osmolar
contrast media (LOCM), according to research presented at EuroPCR 2015.
The results of this study are highly encouraging and support the use of isosmolar contrast media in high-risk percutaneous coronary intervention.
The results of this study are highly encouraging and support the use of isosmolar contrast media in high-risk percutaneous coronary intervention.
The study, funded by GE Healthcare, retrospectively analysed data from
the Premier hospital database in the USA, which describes 334,001
angioplasty procedures that took place between January 2008 and
September 2013. The researchers found that 10.5% fewer major adverse
renal and cardiac events (MARCE) occurred when Visipaque was used
compared with LOCM (p<0.01). The difference was even greater between
those hospitals that solely used either IOCM or LOCM, with 26.7% fewer
MARCE taking place in the IOCM group compared with the LOCM group. In
addition, 2.7% and 0.6% fewer renal failure and kidney injury events,
respectively, were observed with the use of IOCM compared with LOCM.
The results of this study are highly encouraging and support the use of isosmolar contrast media in high-risk percutaneous coronary intervention. These data suggest that prior studies with signal of reduced risk of contrast-induced acute kidney injury with Visipaque do indeed translate into a reduction in clinically meaningful MARCE.
These findings are likely to be of great benefit to patients undergoing angioplasty procedures, especially those who are more vulnerable. Indeed, the data showed that angioplasty procedures that used Visipaque tended to be performed in older (66.8 versus 63.8 years; p<0.01) and sicker patients based on the Charlson Comorbidity Index (4.0 versus 3.4; p<0.01). Compared with LOCM, IOCM was also used in more emergency procedures and in more patients who were classified as ‘major’ or ‘extreme’ according to the 3MTM APR-DRG indices of mortality and severity of illness.
The results of this study are highly encouraging and support the use of isosmolar contrast media in high-risk percutaneous coronary intervention. These data suggest that prior studies with signal of reduced risk of contrast-induced acute kidney injury with Visipaque do indeed translate into a reduction in clinically meaningful MARCE.
These findings are likely to be of great benefit to patients undergoing angioplasty procedures, especially those who are more vulnerable. Indeed, the data showed that angioplasty procedures that used Visipaque tended to be performed in older (66.8 versus 63.8 years; p<0.01) and sicker patients based on the Charlson Comorbidity Index (4.0 versus 3.4; p<0.01). Compared with LOCM, IOCM was also used in more emergency procedures and in more patients who were classified as ‘major’ or ‘extreme’ according to the 3MTM APR-DRG indices of mortality and severity of illness.
No comments:
Post a Comment